Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | NGM707 |
| Synonyms | |
| Therapy Description |
NGM707 is a monoclonal antibody with dual specificity to both ILT2 and LILRB2 (ILT4), which inhibits ligand binding including both classical and non-classical MHC-I molecules, potentially resulting in the activation of an immune cell response (Cancer Res 2021;81(13_Suppl):Abstract nr LB156). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| NGM707 | NGM-707|NGM 707 | LILRB2 Antibody 12 | NGM707 is a monoclonal antibody with dual specificity to both ILT2 and LILRB2 (ILT4), which inhibits ligand binding including both classical and non-classical MHC-I molecules, potentially resulting in the activation of an immune cell response (Cancer Res 2021;81(13_Suppl):Abstract nr LB156). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04913337 | Phase Ib/II | NGM707 + Pembrolizumab NGM707 | Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | Active, not recruiting | USA | 2 |